Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome
Cutaneous-skeletal hypophosphatemia syndrome (CSHS) is a rare bone disorder featuring fibroblast growth factor-23 (FGF23)-mediated hypophosphatemic rickets.We report a 2-year, 10-month-old girl with Back Cinch CSHS treated with burosumab, a novel human monoclonal antibody targeting FGF23.This approach was associated with rickets healing, improvemen